This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients (GL-CLB-001)

This study has been terminated.
(Unsatisfactory enrollment)
Novartis Pharmaceuticals
Information provided by:
Jewish General Hospital Identifier:
First received: November 15, 2007
Last updated: April 14, 2010
Last verified: November 2007
The purpose of this study is to determine maximum tolerated dose of Gleevec in combination with Chlorambucil in previously treated CLL patients.

Condition Intervention Phase
Chronic Lymphocytic Leukemia Drug: Gleevec and Chlorambucil Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I-II Trial of Gleevec (Imatinib Mesylate) in Combination With Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia (CLL) Patients

Resource links provided by NLM:

Further study details as provided by Jewish General Hospital:

Primary Outcome Measures:
  • Measure number of patients at maximum tolerated dose of Gleevec in combination with chlorambucil [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Report adverse events as a measure of safety [ Time Frame: 6 months ]
  • Report response to treatment as a measure of efficacy [ Time Frame: 6 months ]
  • Report level of gleevec concentration at different doses as a measure of pharmacokinetics [ Time Frame: 1 month ]

Enrollment: 13
Study Start Date: October 2005
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I
Gleevec Chlorambucil
Drug: Gleevec and Chlorambucil
The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
Other Names:
  • Gleevec (imatinib mesylate)
  • Chlorambucil

Detailed Description:
A recent study by Aloyz et al demonstrated a synergistic effect of imatinib on chlorambucil-mediated cytotoxicity in CLL cells in vitro. Imatinib inhibits c-abl and sensitizes cells to chlorambucil. The Phase I component of the study will determine the maximum tolerated dose and recommended Phase II dose of Gleevec when used in combination with chlorambucil. Once the maximum tolerated dose has been determined, a total of 16 patients will be enrolled in the Phase II component of the study. This study will determine the dose limiting toxicities, pharmacokinetics and pharmacodynamics of Gleevec in combination with chlorambucil.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • B-cell chronic lymphocytic leukemia (a) Rai stage 0-II with indication for treatment by NCI Working Group Criteria: or (b) Rai stage III or IV.
  • Received a minimum of one prior chemotherapy regimen. Prior treatment with corticosteroids, immunotherapies, monoclonal antibodies or radiation therapy is permitted.
  • White blood cell count > 25 x 10^9/L
  • ECOG 0, 1,or 2.
  • Adequate renal and hepatic function
  • Platelets > 75 x 10^9/L, transfusion independent.
  • Neutrophils > 1.0 x 10^9/L, transfusion independent

Exclusion Criteria:

  • Documented prolymphocytic leukemia (PLL; prolymphocytes, 55% in blood)
  • Active cardiovascular disease as defined by NYHA class III-IV categorization.
  • Intercurrent illness or medical condition precluding safe administration of ribavirin.
  • Concurrent use of chronic steroids, except as replacement therapy for adrenal insufficiency
  • Known infection with HIV, Hepatitis B or C.
  • Concurrent malignancy (other than resected basal or squamous cell skin cancers or in-situ carcinoma).
  • Received any previous therapy for CLL within 28 days prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00558961

Canada, Quebec
Charles Lemoyne Hospital
Greenfield Park, Quebec, Canada, J4V 2H1
Jewish General Hospital
Montreal, Quebec, Canada, H4T 1E2
Sponsors and Collaborators
Jewish General Hospital
Novartis Pharmaceuticals
Principal Investigator: Sarit Assouline, MD Jewish General Hospital
Study Director: Lawrence Panasci, MD Jewish General Hospital
  More Information

Publications: Identifier: NCT00558961     History of Changes
Other Study ID Numbers: CR0506PI
Study First Received: November 15, 2007
Last Updated: April 14, 2010

Keywords provided by Jewish General Hospital:
chronic lymphocytic leukemia

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents processed this record on September 21, 2017